Pluristem Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

HAIFA, Israel, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company's common stock and one warrant to purchase 0.35 of a share of the company's common stock, at a purchase price of $4.00 per unit for an aggregate gross offering amount of $32 million. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions. Each warrant will be exercisable for a period of 5 years following the issuance thereof at an exercise price of $5.00. The company has also granted the underwriters a 30-day option to purchase up to 1,200,000 shares of common stock and/or warrants to purchase up to 420,000 shares of common stock to cover over-allotments, if any.

Jefferies & Company, Inc. is acting as sole book-running manager for the offering. Oppenheimer & Co. Inc. is acting as co-lead manager for the offering. Needham & Company, LLC and Maxim Group LLC are acting as co-managers for the offering. In addition, Leader Capital Markets Ltd. is acting as a financial advisor to the company in connection with the offering.

The securities described above are being offered by Pluristem pursuant to a "shelf" registration statement previously declared effective by the Securities and Exchange Commission (SEC) on October 20, 2011 (File No. 333-177009). Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that Pluristem has filed with the SEC for more complete information about Pluristem and this offering. A final prospectus supplement and an accompanying prospectus will be filed with the SEC in connection with the offering. Once filed, copies of the final prospectus supplement relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov .

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

If you liked this article you might like

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stock Futures Little Changed as Oil Prices Level Off